US-based pharmaceutical firm Mylan has introduced its Lamivudine Tablets, 100mg, which is the generic version of GlaxoSmithKline's Epivir-HBV.
Subscribe to our email newsletter
The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA)for Lamivudine Tablets to treat chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.
According to IMS Health, Lamivudine Tablets, 100mg, had US sales of around $18.1m for the 12 months ending 30 September 2014.
Around 284 of the comapny’s ANDAs are still awaiting clearance from the US FDA that represent $109.1bn in annual sales, with 44 of them being potential first-to-file opportunities, signifying $29.3bn in annual brand sales, for the year ending 30 June 2014.
The company provides a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications.
Additionally, the company provides a wide range of antiretroviral therapies, upon which about 40% of HIV/AIDS patients in developing countries depend.
The company also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 140 countries and territories.